Rocket Pharmaceuticals (RCKT) Highlights Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 'Process B' for Fanconi Anemia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Rocket Pharmaceuticals (RCKT) Highlights Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 'Process B' for Fanconi Anemia

Rocket Pharmaceuticals Presents Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 “Process B” for Fanconi Anemia at 61st American Society of Hematology Annual Meeting

December 8, 2019 6:00 PM EST

US Phase 1 Trial Establishes Feasibility of Commercial Process B Vector/Cell Manufacturing in FA

Preliminary Data Demonstrate Evidence of Early Engraftment Without Conditioning Four to Six Months after Administration of Gene Therapy

Process B Drug Product VCN 2-3x Higher Than That Administered to Optimally-Treated Process A Patients

NEW YORK--(BUSINESS WIRE)-- Rocket Pharmaceuticals,... More